{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:27:37Z","timestamp":1773815257761,"version":"3.50.1"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma and Myeloma"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.3816\/clm.2007.s.034","type":"journal-article","created":{"date-parts":[[2008,9,13]],"date-time":"2008-09-13T01:21:23Z","timestamp":1221268883000},"page":"S57-S62","source":"Crossref","is-referenced-by-count":50,"special_numbering":"S2","title":["Update of the M. D. Anderson Cancer Center Experience with Hyper-CVAD and Rituximab for the Treatment of Mantle Cell and Burkitt-Type Lymphomas"],"prefix":"10.3816","volume":"8","author":[{"given":"Luis","family":"Fayad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Romaguera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2007.s.034_bib1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1046\/j.1365-2559.2000.00895.x","article-title":"The World Health Organization for neoplastic diseases of the haematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting, Arlie House, Virginia, November 1997","volume":"36","author":"Harris","year":"2000","journal-title":"Histopathology"},{"key":"10.3816\/CLM.2007.s.034_bib2","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"Lenz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.s.034_bib3","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa055759","article-title":"Molecular diagnosis of Burkitt's lymphoma","volume":"354","author":"Dave","year":"2006","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2007.s.034_bib4","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1200\/JCO.1996.14.3.925","article-title":"Adults and children with small noncleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen","volume":"14","author":"Magrath","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.s.034_bib5","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1200\/JCO.1999.17.8.2461","article-title":"Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia","volume":"17","author":"Thomas","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.s.034_bib6","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1200\/JCO.1998.16.12.3803","article-title":"Hyper-CVAD and highdose methotrexate\/cytarabine followed by stem cell transplantation: an active regimen for aggressive mantle cell lymphoma","volume":"16","author":"Khouri","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.s.034_bib7","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1002\/cncr.20668","article-title":"Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"101","author":"Kantarjian","year":"2004","journal-title":"Cancer"},{"key":"10.3816\/CLM.2007.s.034_bib8","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1182\/blood-2003-12-4428","article-title":"Outcome of the hyper-CVAD regimens in lymphoblastic lymphoma","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.034_bib9","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High-rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine","volume":"23","author":"Romaguera","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.s.034_bib10","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","article-title":"Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma of acute lymphoblastic leukemia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"key":"10.3816\/CLM.2007.s.034_bib11","doi-asserted-by":"crossref","first-page":"258","DOI":"10.6004\/jnccn.2006.0025","article-title":"Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology","volume":"4","author":"Zelenetz","year":"2006","journal-title":"J Natl Compr Canc Netw"},{"key":"10.3816\/CLM.2007.s.034_bib12","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.20.5.1288","article-title":"Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma. Molecular responses are not predictive of progression-free survival","volume":"20","author":"Howard","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.s.034_bib13","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1093\/annonc\/mdl127","article-title":"Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network","volume":"9","author":"Kahl","year":"2006","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2007.s.034_bib14","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1002\/cncr.11838","article-title":"Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score","volume":"98","author":"Khouri","year":"2003","journal-title":"Cancer"},{"key":"10.3816\/CLM.2007.s.034_bib15","doi-asserted-by":"crossref","first-page":"747a","DOI":"10.1182\/blood.V104.11.2732.2732","article-title":"Subtype adjusted therapy improves outcome of elderly patients with acute lymphoblastic leukemia","volume":"104","author":"Hoelzer","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.034_bib16","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.s.034_bib17","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/cncr.21595","article-title":"Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"key":"10.3816\/CLM.2007.s.034_bib18","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1182\/blood-2004-01-0039","article-title":"Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas","volume":"104","author":"Teeling","year":"2004","journal-title":"Blood"}],"container-title":["Clinical Lymphoma and Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011701500?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011701500?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T07:52:24Z","timestamp":1588924344000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1557919011701500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":18,"alternative-id":["S1557919011701500"],"URL":"https:\/\/doi.org\/10.3816\/clm.2007.s.034","relation":{},"ISSN":["1557-9190"],"issn-type":[{"value":"1557-9190","type":"print"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}